Bio-Rad Laboratories Inc Dossier
Qualitative Analysis
Business overview
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostics markets. Headquartered in Hercules, California, the company operates a global network with approximately 7,400 employees. Bio-Rad's operations are divided into two primary segments: Clinical Diagnostics (representing approximately 60% of sales), which provides test systems, informatics, and specialized quality controls for clinical laboratories; and Life Sciences (representing approximately 40% of sales), which develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food safety. The company is geographically diverse, with major markets in the Americas, Europe, and Asia. Additionally, Bio-Rad holds a significant (~33%) equity investment in Sartorius AG, a major lab and bioprocessing supplier.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting from a legacy reagent supplier to a precision-medicine enabler by scaling the ddPCR platform, specifically driving competitive wins and qPCR conversions with the QX700 and QX600 series.
Expected impact: Increases high-margin recurring consumables revenue and expands clinical diagnostics market share.
Redistributing manufacturing and sourcing footprints to mitigate tariff exposures and lower the overall cost base.
Expected impact: Mitigates tariff headwinds and improves long-term gross margins.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To complement Bio-Rad's existing digital PCR portfolio and accelerate the development of next-generation digital PCR solutions with high multiplexing and automation capabilities.
Financial impact: Acquired for $225 million in cash plus potential future contingent milestone payments of up to $50 million.
Strategic Partnerships
To distribute and develop in vitro diagnostic (IVD) oncology assays, advancing Bio-Rad's clinical diagnostics strategy for oncology applications.
Terms: Terms not publicly disclosed
Collaborating on Droplet Digital PCR (ddPCR) for IVD oncology assays to strengthen presence in the precision medicine market.
Terms: Terms not publicly disclosed